Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor γδT Cell Infusion for Relapsed/Refractory Leukemia After Allo-HSCT
NCT04439721Phase 1Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- May 2020
- Primary completion
- May 2021
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of donor gamma-delta T cells in B-cell leukemia (BCL) and acute leukemia, sponsored by PersonGen BioTherapeutics. Primary endpoints: Dose Limiting Toxicity at 4 weeks and Incidence of Serious Adverse Events at 4 weeks. Status: unknown.
02
Drugs
donor gamma-delta T cells
03
Conditions
B-cell leukemia (BCL)acute leukemia
Beyond the preview
Go deeper on NCT04439721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439721.